EpiGenesis Pharmaceuticals Inc. is developing treatments based on epigenetics, which seeks to understand the complex series of gene expression events that enables a single cell to develop into an entire human being.

In particular, the company is targeting discordant gene expression, where a gene is expressed out of turn. For example, in asthma, genes normally involved in the inflammatory response to protect the lung from attack by pathogens are inappropriately expressed in the absence of such pathogens.